Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Kidney cancer: overall survival is an unsuitable primary end point.

Literature DB >> 20616795

Kidney cancer: overall survival is an unsuitable primary end point.

Abstract

Final results of the CALGB 90206 and AVOREN trials have failed to demonstrate an overall survival benefit for bevacizumab plus interferon compared to interferon monotherapy in patients with metastatic renal cell carcinoma. Progression-free survival or objective response rate might be more suitable primary end points in phase III trials.

Entities: Chemical Disease Species

Mesh：

Year: 2010 PMID： 20616795 DOI： 10.1038/nrurol.2010.84

Source DB: PubMed Journal: Nat Rev Urol ISSN： 1759-4812 Impact factor: 14.432

9 in total

1. Sorafenib in advanced clear-cell renal-cell carcinoma.

Authors: Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski
Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245

2. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.

Authors: Brian I Rini; Susan Halabi; Jonathan E Rosenberg; Walter M Stadler; Daniel A Vaena; Laura Archer; James N Atkins; Joel Picus; Piotr Czaykowski; Janice Dutcher; Eric J Small
Journal: J Clin Oncol Date: 2010-04-05 Impact factor: 44.544

3. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.

Authors: Bernard Escudier; Joaquim Bellmunt; Sylvie Négrier; Emilio Bajetta; Bohuslav Melichar; Sergio Bracarda; Alain Ravaud; Sophie Golding; Sangeeta Jethwa; Vesna Sneller
Journal: J Clin Oncol Date: 2010-04-05 Impact factor: 44.544

4. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

Authors: Bernard Escudier; Anna Pluzanska; Piotr Koralewski; Alain Ravaud; Sergio Bracarda; Cezary Szczylik; Christine Chevreau; Marek Filipek; Bohuslav Melichar; Emilio Bajetta; Vera Gorbunova; Jacques-Olivier Bay; Istvan Bodrogi; Agnieszka Jagiello-Gruszfeld; Nicola Moore
Journal: Lancet Date: 2007-12-22 Impact factor: 79.321

5. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.

Authors: Brian I Rini; Susan Halabi; Jonathan E Rosenberg; Walter M Stadler; Daniel A Vaena; San-San Ou; Laura Archer; James N Atkins; Joel Picus; Piotr Czaykowski; Janice Dutcher; Eric J Small
Journal: J Clin Oncol Date: 2008-10-20 Impact factor: 44.544

6. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.

Authors: Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Roberto Pili; Georg A Bjarnason; Xavier Garcia-del-Muro; Jeffrey A Sosman; Ewa Solska; George Wilding; John A Thompson; Sindy T Kim; Isan Chen; Xin Huang; Robert A Figlin
Journal: J Clin Oncol Date: 2009-06-01 Impact factor: 44.544

7. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

Authors: Gary Hudes; Michael Carducci; Piotr Tomczak; Janice Dutcher; Robert Figlin; Anil Kapoor; Elzbieta Staroslawska; Jeffrey Sosman; David McDermott; István Bodrogi; Zoran Kovacevic; Vladimir Lesovoy; Ingo G H Schmidt-Wolf; Olga Barbarash; Erhan Gokmen; Timothy O'Toole; Stephanie Lustgarten; Laurence Moore; Robert J Motzer
Journal: N Engl J Med Date: 2007-05-31 Impact factor: 91.245

8. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.

Authors: Robert J Motzer; Bernard Escudier; Stéphane Oudard; Thomas E Hutson; Camillo Porta; Sergio Bracarda; Viktor Grünwald; John A Thompson; Robert A Figlin; Norbert Hollaender; Gladys Urbanowitz; William J Berg; Andrea Kay; David Lebwohl; Alain Ravaud
Journal: Lancet Date: 2008-07-22 Impact factor: 79.321

9. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.

Authors: Brian I Rini; Darrel P Cohen; Dongrui R Lu; Isan Chen; Subramanian Hariharan; Martin E Gore; Robert A Figlin; Michael S Baum; Robert J Motzer
Journal: J Natl Cancer Inst Date: 2011-04-28 Impact factor: 13.506